Results 31 to 40 of about 7,735 (172)

Determination of Dabigatran Concentration in Human Plasma and Breast Milk

International Journal of Analytical Chemistry, 2021
Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk
F. Sidgwick, A. Porter, P. Ayuk, F. Kamali, A. Truemann   +4 more
doaj   +1 more source

Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting

Frontiers in Medicine, 2020
Background: Idarucizumab has been included in guidelines for the management of bleeding or surgical procedure in dabigatran-treated patients without need for biological monitoring.
Nicolas Gendron, Nicolas Gendron, Richard Chocron, Richard Chocron, Paul Billoir, Julien Brunier, Laurence Camoin-Jau, Marie Tuffigo, Dorothée Faille, Dorothée Faille, Dorian Teissandier, Juliette Gay, Juliette Gay, Emmanuelle de Raucourt, Emmanuelle de Raucourt, Ludovic Suner, Corentin Bonnet, Anne-Céline Martin, Anne-Céline Martin, Dominique Lasne, Chayma Ladhari, Aurélien Lebreton, Laurent Bertoletti, Laurent Bertoletti, Nadine Ajzenberg, Nadine Ajzenberg, Pascale Gaussem, Pascale Gaussem, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Pierre-Emmanuel Morange, Véronique Le Cam Duchez, Alain Viallon, Pierre-Marie Roy, Pierre-Marie Roy, Agnès Lillo-le Louët, Agnès Lillo-le Louët, David M. Smadja, David M. Smadja, David M. Smadja   +39 more
doaj   +1 more source

Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations

Clinical and Applied Thrombosis/Hemostasis, 2019
To describe the effect of dabigatran on thrombin time (TT) reagents at different concentrations of thrombin. Pooled normal plasma enriched with dabigatran was dissolved in dimethylsulfoxide (DMSO) at concentrations of 0, 20, 50, 100, 200, 300, and 500 ng/
Xiaoping Xu, Qian Liang
doaj   +1 more source

Flow Cytometric Assessment of Endothelial and Platelet Microparticles in Patients With Atrial Fibrillation Treated With Dabigatran

Clinical and Applied Thrombosis/Hemostasis, 2020
The prothrombotic state in patients with atrial fibrillation (AF) is related to endothelial injury, the activation of platelets and the coagulation cascade.
Aleksandra Lenart-Migdalska MD, Leszek Drabik MD, PhD, Magdalena Kaźnica-Wiatr MD, PhD, Lidia Tomkiewicz-Pająk MD, PhD, Piotr Podolec MD, PhD, Maria Olszowska MD, PhD   +5 more
doaj   +1 more source

The impact of ABCB1 and CES1 polymorphisms on the safety of dabigatran in patients with non-valvular atrial fibrillation

BMC Cardiovascular Disorders, 2022
Background This study aimed to analyze associations between genetic variants and plasma concentrations along with clinical outcomes in dabigatran in patients with non-valvular atrial fibrillation (NVAF).
Zhu Zhu, Chenyue Qian, Cunjing Su, Hong Tao, Jiaojiao Mao, Zhening Guo, Xinyi Zhu, Jie Pan   +7 more
doaj   +1 more source

Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies, Elin Haf Davies, Dyfrig A. Hughes   +2 more
wiley   +1 more source

Dabigatran étexilate et itraconazole

, 2022
International audienceDabigatran étexilate et itraconazole Le dabigatran étexilate est un substrat de la glycoprotéine P (P-gp), une pompe d'efflux située au niveau intestinal, alors que l'itraconazole est un inhibiteur puissant de la P-gp.
Legeay, Samuel, Faure, Sébastien
core   +1 more source

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER

Рациональная фармакотерапия в кардиологии, 2016
Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed.
I. S. Yavelov
doaj   +1 more source

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

BMC Cardiovascular Disorders, 2020
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF) taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and bleeding risk.
Alexandros Briasoulis, Yubo Gao, Chakradhari Inampudi, Paulino Alvarez, Rabea Asleh, Elizabeth Chrischilles, Enrique C. Leira, Mary Vaughan-Sarrazin   +7 more
doaj   +1 more source

Current practice and guideline adherence in renal dose adjustment for patients with chronic kidney disease: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims To quantify prescribing adherence to renal dosing recommendations in adults with chronic kidney disease (CKD; Stage 3 and above) and to evaluate the clinical consequences of non‐adherence. Methods This systematic review and meta‐analysis was conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42025620883).
Hager ElGeed, Ahmed Tehemar, Mohamed Gasimelseed, Ahmed Gharaibeh, Muhammad Abdul Hadi, Kazeem Yusuff, Amani Zidan, Ahmed Awaisu   +7 more
wiley   +1 more source